🚀 VC round data is live in beta, check it out!
Oncoinvent Valuation Multiples
Discover revenue and EBITDA valuation multiples for Oncoinvent and similar public comparables like Lantern Pharma, Nanogroup, Poltreg, Vistagen Therapeutics and more.
Oncoinvent Overview
About Oncoinvent
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The product candidate, Radspherin, uses the alpha-emitting radionuclide radium-224 to directly target micrometastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting.
Founded
2007
HQ
Employees
13
Website
Sectors
Financials (LTM)
EV
$3M
Oncoinvent Financials
Oncoinvent reported last 12-month revenue of $3M and negative EBITDA of ($15M).
In the same LTM period, Oncoinvent generated $3M in gross profit, ($15M) in EBITDA losses, and had net loss of ($16M).
Revenue (LTM)
Oncoinvent P&L
In the most recent fiscal year, Oncoinvent reported revenue of $3M and EBITDA of ($13M).
Oncoinvent expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3M | XXX | $3M | XXX | XXX | XXX |
| Gross Profit | $3M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($15M) | XXX | ($13M) | XXX | XXX | XXX |
| EBITDA Margin | (513%) | XXX | (448%) | XXX | XXX | XXX |
| EBIT Margin | (552%) | XXX | (488%) | XXX | XXX | XXX |
| Net Profit | ($16M) | XXX | ($16M) | XXX | XXX | XXX |
| Net Margin | (537%) | XXX | (554%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Oncoinvent Stock Performance
Oncoinvent has current market cap of $22M, and enterprise value of $3M.
Market Cap Evolution
Oncoinvent's stock price is $4.81.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3M | $22M | -1.1% | XXX | XXX | XXX | $-3.62 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOncoinvent Valuation Multiples
Oncoinvent trades at 1.1x EV/Revenue multiple, and (0.2x) EV/EBITDA.
EV / Revenue (LTM)
Oncoinvent Financial Valuation Multiples
As of April 10, 2026, Oncoinvent has market cap of $22M and EV of $3M.
Equity research analysts estimate Oncoinvent's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oncoinvent has a P/E ratio of (1.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $22M | XXX | $22M | XXX | XXX | XXX |
| EV (current) | $3M | XXX | $3M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | (0.2x) | XXX | (0.3x) | XXX | XXX | XXX |
| EV/EBIT | (0.2x) | XXX | (0.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 1.1x | XXX | — | XXX | XXX | XXX |
| P/E | (1.3x) | XXX | (1.3x) | XXX | XXX | XXX |
| EV/FCF | (0.2x) | XXX | (0.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Oncoinvent Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Oncoinvent Margins & Growth Rates
Oncoinvent's revenue in the last 12 month grew by 7%.
Oncoinvent's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $1.3M for the same period.
Oncoinvent's rule of 40 is (452%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oncoinvent's rule of X is (406%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Oncoinvent Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | (513%) | XXX | (448%) | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | 16% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (452%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (406%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 23% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 225% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 571% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Oncoinvent Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Lantern Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanogroup | XXX | XXX | XXX | XXX | XXX | XXX |
| Poltreg | XXX | XXX | XXX | XXX | XXX | XXX |
| Vistagen Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| VYNE Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oncoinvent M&A Activity
Oncoinvent acquired XXX companies to date.
Last acquisition by Oncoinvent was on XXXXXXXX, XXXXX. Oncoinvent acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Oncoinvent
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOncoinvent Investment Activity
Oncoinvent invested in XXX companies to date.
Oncoinvent made its latest investment on XXXXXXXX, XXXXX. Oncoinvent invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Oncoinvent
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Oncoinvent
| When was Oncoinvent founded? | Oncoinvent was founded in 2007. |
| Where is Oncoinvent headquartered? | Oncoinvent is headquartered in Norway. |
| How many employees does Oncoinvent have? | As of today, Oncoinvent has over 13 employees. |
| Is Oncoinvent publicly listed? | Yes, Oncoinvent is a public company listed on Oslo Børs. |
| What is the stock symbol of Oncoinvent? | Oncoinvent trades under ONCIN ticker. |
| When did Oncoinvent go public? | Oncoinvent went public in 2017. |
| Who are competitors of Oncoinvent? | Oncoinvent main competitors are Lantern Pharma, Nanogroup, Poltreg, Vistagen Therapeutics. |
| What is the current market cap of Oncoinvent? | Oncoinvent's current market cap is $22M. |
| What is the current revenue of Oncoinvent? | Oncoinvent's last 12 months revenue is $3M. |
| What is the current revenue growth of Oncoinvent? | Oncoinvent revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Oncoinvent? | Current revenue multiple of Oncoinvent is 1.1x. |
| Is Oncoinvent profitable? | No, Oncoinvent is not profitable. |
| What is the current EBITDA of Oncoinvent? | Oncoinvent has negative EBITDA and is not profitable. |
| What is Oncoinvent's EBITDA margin? | Oncoinvent's last 12 months EBITDA margin is (513%). |
| What is the current EV/EBITDA multiple of Oncoinvent? | Current EBITDA multiple of Oncoinvent is (0.2x). |
| What is the current FCF of Oncoinvent? | Oncoinvent's last 12 months FCF is ($15M). |
| What is Oncoinvent's FCF margin? | Oncoinvent's last 12 months FCF margin is (487%). |
| What is the current EV/FCF multiple of Oncoinvent? | Current FCF multiple of Oncoinvent is (0.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.